U.S. Gene Editing Market - Industry Outlook & Forecast 2022-2027

196 pages

48 tables

86 charts

4 region

1 countries

43 company

4 segments

Purchase Options

$3750.00
$4250.00
$5250.00
$1500.00

Have a question?

Please get in touch with our team in case of any queries

+1-312-235-2040

THE U.S. GENE EDITING MARKET SIZE WAS VALUED AT USD 2.90 BILLION IN 2021 AND IS EXPECTED TO REACH USD 9.16 BILLION BY 2027, GROWING AT A CAGR OF 21.13%.

The U.S. Gene Editing Market Share, Size, & Trends Analysis Report by

  • Products: Reagents & Consumables, Equipment & Software, And Services
  • Technology: CRISPER, TALEN, ZFN, And Others
  • Application: Drug Discovery & Development (DDD), Animal Gene Editing, Plant Gene Editing, And Others
  • End User: Pharma & Biotech Companies (PBC), Academic & Research Institutes (ARI), Animal & Plant Biotech Companies (APBC), And CROs/CDMOs

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2027

Customize this Report

This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize

U.S. GENE EDITING MARKET REPORT SCOPE

REPORT ATTRIBUTEDETAILS
Market Size (2027)USD 9.16 Billion
Market Size (2021)USD 2.90 Billion
CAGR (2021-2027)21.13%
Base Year2021
Forecast Year2022-2027
Market SegmentsProducts, Technology, Application, and End User
Geographic AnalysisUnited States
KEY PLAYERSAgilent Technologies, Creative Biogene, Genscript, Merck KGaA, Thermo Fisher Scientific, and Takara Bio
Interested in this Report?

Download a Sample!

The U.S. gene editing market was valued at USD 2.90 billion in 2021 and is expected to reach USD 9.16 billion by 2027, growing at a CAGR of 21.13% from 2021-2027. Growth in the gene editing market is fueled by increasing demand for synthetic genes in the U.S. Genomics can be used to identify genetic abnormalities in humans, drug discovery, agriculture, veterinary medicine, and forensics. Gene editing requires tools and techniques that make unique changes to the DNA sequence of an organism's genes, fundamentally altering the genetic blueprint. Unlike genetic engineering, which randomly incorporates genetic material into the host genome, gene editing aims to make changes at specific target locations.

Genome editing technology is a technique for target gene modification that allows the knockout and addition of specific fragments of DNA. This technique is widely used in biomedical research, clinics, and agriculture. A growing preference for personalized medicine, rare disease treatment research, rising R&D spending and growth in the pharmaceutical and biotech industries, rapid advances in sequencing and genome editing technologies, and increasing use of products derived from genetically modified organisms. These are some of the factors that are boosting the growth of the U.S. gene editing market.

MARKET TRENDS AND OPPORTUNITIES

The Emergence of Novel Gene Editing Tools
CRISPR changes the way scientists work on gene editing, providing unprecedented accuracy. However, CRISPR technology is not certain and has limitations that make the leap from gene therapy and cell therapy laboratories to the bedside.

Base editing is an innovative technology that can create gene knockouts and correct specific errors and mutations in the DNA of whole cells. Single nucleotide polymorphisms are highly pathogenic mutations that cause human illness and require only a single nucleotide change to correct the mutation.

In October 2019, David Liu's postdoctoral fellow Andrew Anzalone and his colleagues published the development and application of prime editing on Nature's website. Prime editing is a gene editing technique that can accurately perform small, targeted insertions, deletions, and base swaps.

The development of prime editing is a powerful add-on to the genome editing toolbox. Prime editing is the latest tool developed to address CRISPR/Cas drawbacks and calibrate the genome editing process. For educational use, the technology can be presently achieved by the Add gene repository.

Increasing Pharma/Biotech, Venture Capital, & Government Funding for Gene Editing Projects
Genome editing aims to modify the DNA sequence so cells can make the correct protein again. NIH created the SCGE program in January 2018 to improve genome editing technology and make genome editing therapies more widely available. Genome editing has a great potential to change the treatment environment for both common and rare diseases. Gene editing is in its infancy, and these newly funded projects promise better strategies to address various challenges, including the right genes in the genome. Over the past decade, the U.S. gene editing market is witnessing many new investments from governments, private equities, and venture capitalists. For instance, the number of VC deals increased from 1 in 2012 to 29 in 2021, and the total amount of VC deals since 2012 reached USD 3.2 billion. In 2021 alone, more than USD 1.3 billion was raised, an increase of more than 250% from 2020 (USD 500 million).

The most exciting developments in CRISPR therapeutics often come from start-ups. However, CRISPR treatments are also attracting interest from big pharmaceutical companies. Start-ups and big pharma often choose to partner. Some examples of small/large partnerships include Beam Therapeutics-Pfizer, Metagenomi-Moderna, CRISPR Therapeutics-Vertex Pharmaceuticals, Mammoth Biosciences-Bayer, Intellia Therapeutics-Regeneron Pharmaceuticals, Intellia-Novartis, and Caribou Biosciences-AbbVie.

Advancements in Gene editing technologies have turned up novel gene editing technology that has opened new and stimulating opportunities in drug discovery and medicine. The immense potential of gene editing technologies, like CRISPR, base editing, and prime editing is starting to be accomplished in treating rare and complex diseases. Arizton expects increased activity in this area in the coming years, including additional investment in gene editing companies developing gene-editing technologies.

Diversified Application Areas of Gene Editing
Genome editing is widely used in studying a wide variety of organisms. For example, CRISPR creates "knockout" models of various animal diseases, allowing researchers to study the underlying genetic cause. It also modifies the genes of specific tissues and organs, focusing on the criminal's genes to facilitate disease research, creating disease cell models like human pluripotent stem cells, and creating pig organs.

Several technologies, including zinc finger endonucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and clustered, regularly spaced, short-interval palindrome repeat / CRISPR-related nucleases (CRISPR / Cas) systems are used to achieve gene editing. Due to its simple design, rapid implementation, low cost, and robust scalability, researchers see the CRISPR / Cas system as an innovative gene-editing toolbox that extends to almost any genome target. This system is widely used, especially in cancer research, and is a potential approach for diagnosing and treating cancer.

SEGMENTATIONS ANALYSIS

INSIGHTS BY PRODUCT
The reagents & consumables segment accounted for a significant share of around 67.11% of the U.S. gene editing market. The segment is estimated to be higher because of gene editing technology based on programmable nucleases such as meganucleases, zinc finger nucleases (ZFNs), and transcriptional activator-like effector nucleases (TALENs), and CRISPR-related nucleases Cas9 that spreads the possibility of therapeutic gene editing in affected cells and tissues. It results in the removal or correction of harmful mutations or the insertion of protective mutations. Gene editing is widely used in drug discovery and development, diagnosis, crop improvement and seed production, and livestock. The CRISPR / Cas9 KO Kit is a highly efficient and accurate gene editing kit based on the latest artificial endonuclease CRISPR / Cas9. Compared to traditional TALEN and ZFN gene knockout technologies, the CRISPR / Cas9 KO kit is easier to operate and has the highest knockout efficiency. The CRISPR / Cas9 KO kit can be applied to modify genes in almost all types of mammalian cells. 

INSIGHTS BY TECHNOLOGY
The CRISPR segment accounts for the largest share of around 63.49% in the U.S. gene editing market under the technology category. This segment is estimated to be higher because CRISPR has revolutionized research and practice outcomes in biology, especially in genome editing and genetic engineering. The CRISPR-related gene (Cas gene) was identified in 2002, and further research has provided a better understanding of the structure and function of CRISPR and CRISPR-related (Cas) proteins. CRISPR technology-based gene editing was first demonstrated in 2013, and the technology has evolved rapidly.

Emerging technologies such as CRISPR-Cas9 are vital to unlocking potential drug discovery targets and can significantly impact modern drug discovery and development. CRISPR is a genome editing technology that lets scientists precisely modify parts of the DNA sequence in the genome of any organism.

INSIGHTS BY APPLICATION
Among all applications, the drug discovery & development segment holds a major share of 55.71% in the U.S. gene editing market. The segment is estimated to be higher because genome editing has been successfully applied to multiple diseases in preclinical and clinical studies. When assessing the feasibility of genome-editing-based therapies, the therapeutic effect of the gene modification of interest must first be established. Cancer immunotherapy has recently received much attention to leverage the patient's immune system against tumor cells. A promising area of immunotherapy is the application of genetically engineered T cells known as chimeric antigen receptors (CAR) T cells.

INSIGHTS BY END-USER
The pharma & biotech companies segment dominates the U.S. gene editing with a share of 36.52% among all end-user. This segment is estimated to be higher because, in terms of market capitalization, the top U.S.-based biotechnology firm are Johnson & Johnson, Pfizer, Eli Lilly, and Thermo Fisher Scientific. There are some overlaps between biotechnology and pharmaceutical companies. Johnson & Johnson, Pfizer, and Eli Lilly are enormous forces in both industries, and the pharma and biotechnology companies are investing in gene editing companies. With their collaboration, they are developing gene-edited drug products in different therapeutic areas such as cancer, hematology, hereditary eye disorders, NDs, etc.

For instance, In January 2022, Pfizer is the largest pharmaceutical drug company to move into gene editing, putting a big bet on CRISPR-based therapeutics that can correct single-letter typos in DNA and a methodology known as base editing. The company has signed a USD 300 million 4-year deal with Beam Therapeutics that will see the corporations work jointly on three programs for rare liver genetic diseases, the central nervous system, and the muscles.

COMPETITIVE ANALYSIS

Key players in the U.S. gene editing market such as Agilent Technologies, Thermo Fisher Scientific, Genscript, Takara bio, creative Biogene, and merck kgaA collectively account for significant shares in the industry. However, they are facing stiff competition from emerging and existing players. Start-ups and pure gene editing companies are developing their products, expanding their manufacturing facilities, and partnering with big pharma and biotech players, academic/research institutes & laboratories. Technological advances, particularly healthcare solutions, rapidly change the U.S. gene editing market. Market players in the global gene editing market are getting huge investments from VC and the federal government for developing the product portfolio across domains - healthcare, industrial, food & beverages, agriculture, and environment.

Recent Developments and Partnerships

  • The most exciting developments in CRISPR therapeutics often come from start-ups. However, CRISPR is also attracting big pharmaceutical companies to start-up companies. Start-ups and big pharma companies frequently partner with companies offering gene editing approaches and technologies in the U.S. gene editing market.
  • The latest genome-editing company to partner with a major pharmaceutical company is Beam Therapeutics, which pioneered the fundamental editing of human disease. In January 2022, Beam and Pfizer announced their four-year exclusive research collaboration focused on an in vivo baseline treatment program.
  • In January 2022, Bayer and Mammoth Biosciences collaborated on novel gene editing technology. Mammoth Biosciences received USD 40 million to develop an in vivo gene-editing therapy.
  • In November 2021, Moderna collaborated with Metagenomi to add CRISPR-based and other novel gene-editing systems to the company's mRNA/LNP expertise to develop in vivo gene-editing therapeutics.
  • In February 2022, a gene-editing company, Intellia Therapeutics, and ONK Therapeutics, a company developing natural killer (NK) cell therapies in oncology, announced a licensing and collaboration agreement. ONK will take a non-exclusive license to Intelia’s proprietary ex-vivo CRISPR-Cas9-based gene editing platform and its lipid nanoparticle (LNP)-based technologies for the discovery & development of five allogeneic NK cell therapies.

Frequently Asked Questions

What is the expected growth of the U.S. gene editing market?

The U.S. gene editing market size was valued at USD 2.90 billion in 2021 and is expected to reach USD 9.16 billion by 2027.

What is the growth rate of the U.S. gene editing market?

The U.S. gene editing market is growing with a CAGR of 21.13% from 2022 to 2027.

Who are the key players in the U.S. gene editing market?

Key players in the U.S. gene editing market are Agilent Technologies, Creative Biogene, Genscript, Merck KGaA, Thermo Fisher Scientific, and Takara Bio.

What are the latest trends in the U.S. gene editing market?

The emergence of novel gene editing tools, the rise in demand for gene editing in personalized medicine, and increasing pharma/biotech, venture capital, & government funding for gene editing projects are some of the latest trends in the U.S. gene editing market.

What factors will drive the U.S. gene editing market?

The factors driving the U.S. gene editing market are advances in genome editing platforms, increasing target population with rare, genetic & highly complex diseases, and high demand for gene editing in drug discovery & development.

How much is the CRISPR industry worth?

The CRISPR segment dominates the U.S. gene editing market at 63.49%. The CRISPR segment was valued at USD 1.84 billion in 2021.

The U.S. gene editing market is expected to grow at a CAGR of approximately 21.13% from 2022 to 2027.

The following factors are likely to contribute to the growth of the U.S. gene editing market during the forecast period:

  • Advances in Genome Editing Platforms
  • Increasing Target Population with Rare, Genetic & Highly Complex Diseases
  • High Demand for Gene Editing in Drug Discovery & Development
  • Diversified Application Areas of Gene Editing

Base Year: 2021

Forecast Year: 2022-2027

The report considers the present scenario of the U.S. gene editing market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

Key Vendors

  • Agilent Technologies
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • Creative Biogene
  • Genscript
  • Merck KGaA
  • Thermo Fisher Scientific
  • Takara Bio

Other Prominent Vendors

  • Arbor Biotechnologies
    • Business Overview
    • Product Offerings
  • Beam Therapeutics
  • Bluebird Bio
  • Cellectis
  • Caribou Biosciences
  • Charles River Laboratories
  • CRISPR Therapeutics
  • HERA Biolabs
  • Integrated DNA Technologies
  • Lonza
  • New England Biolabs
  • OriGene Technologies
  • Synthego
  • Tecan
  • PerkinElmer
  • Precision BioSciences
  • Intellia Therapeutics
  • Pairwise
  • Sangamo Therapeutics
  • Recombinetics
  • Synbio Technologies

Segmentation by Products

  • Reagents & Consumables
  • Equipment & Software
  • Services

Segmentation by Technology

  • CRISPER
  • TALEN
  • ZFN
  • Others

Segmentation by Application

  • Drug Discovery & Development (DDD)
  • Animal Gene Editing
  • Plant Gene Editing
  • Others

Segmentation by End User

  • Pharma & Biotech Companies (PBC)
  • Academic & Research Institutes (ARI)
  • Animal & Plant Biotech Companies (APBC)
  • CROs/CDMOs

Segmentation by Geography

  • The U.S.

EXHIBIT 1 US SEGMENTATION OF GENE EDITING MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 US GENE EDITING MARKET SIZE ($ BILLION)
EXHIBIT 4 US GENE EDITING MARKET SEGMENTATIONS
EXHIBIT 5 GENE EDITING TECHNIQUES
EXHIBIT 6 IMPACT OF EMERGENCE OF NOVEL GENE EDITING TOOLS
EXHIBIT 7 IMPACT OF USE OF GENE EDITING IN PERSONALIZED MEDICINE
EXHIBIT 8 IMPACT OF INCREASED PHARMA/BIOTECH, VENTURE CAPITAL, & GOVERNMENT FUNDING FOR GENE EDITING PROJECTS
EXHIBIT 9 RECENT VENTURE CAPITAL FUNDINGS ($ MILLION)
EXHIBIT 10 IMPACT OF HIGH NUMBER OF GENE EDITING-BASED INVESTIGATIONAL DRUGS
EXHIBIT 11 MOST TARGETED TREATMENT AREAS IN GENE EDITING
EXHIBIT 12 IMPACT OF ADVANCES IN GENOME EDITING PLATFORMS
EXHIBIT 13 IMPACT OF LARGE TARGET POPULATION WITH RARE GENETIC DISORDERS
EXHIBIT 14 IMPACT OF DEMAND FOR GENE EDITING IN DRUG DISCOVERY & DEVELOPMENT
EXHIBIT 15 IMPACT OF DIVERSE APPLICATIONS OF GENE EDITING
EXHIBIT 16 IMPACT OF HIGH COST & TIME INVOLVED IN GENE EDITING
EXHIBIT 17 COST & TIME INVOLVED IN A CRISPR-BASED EXPERIMENT
EXHIBIT 18 IMPACT OF TECHNICAL CHALLENGES RELATED TO GENE EDITING
EXHIBIT 19 IMPACT OF ETHICAL & SAFETY CONCERNS ASSOCIATED WITH GENE EDITING
EXHIBIT 20 US GENE EDITING MARKET 2021–2027 ($ BILLION)
EXHIBIT 21 US GENE EDITING MARKET BY PRODUCT: MARKET SHARE 2021 & 2027
EXHIBIT 22 US GENE EDITING MARKET BY TECHNOLOGY: MARKET SHARE 2021 & 2027
EXHIBIT 23 US GENE EDITING MARKET BY APPLICATION: MARKET SHARE 2021 & 2027
EXHIBIT 24 US GENE EDITING MARKET BY END-USER: MARKET SHARE 2021 & 2027
EXHIBIT 25 FIVE FORCES ANALYSIS 2021
EXHIBIT 26 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 27 US GENE EDITING MARKET BY PRODUCT
EXHIBIT 28 US GENE EDITING MARKET BY PRODUCT: INCREMENT GROWTH
EXHIBIT 29 US GENE EDITING MARKET BY PRODUCT: ABSOLUTE GROWTH
EXHIBIT 30 US GENE EDITING MARKET BY REAGENTS & CONSUMABLES: INCREMENT & ABSOLUTE GROWTH
EXHIBIT 31 FEATURES OF CAS9 PROTEINS
EXHIBIT 32 US GENE EDITING MARKET BY REAGENTS & CONSUMABLES 2021–2027 ($ BILLION)
EXHIBIT 33 US GENE EDITING MARKET BY EQUIPMENT & SOFTWARE: INCREMENT & ABSOLUTE GROWTH
EXHIBIT 34 US GENE EDITING MARKET BY EQUIPMENT & SOFTWARE 2021–2027 ($ BILLION)
EXHIBIT 35 US GENE EDITING MARKET BY SERVICES: INCREMENT & ABSOLUTE GROWTH
EXHIBIT 36 US GENE EDITING MARKET BY SERVICES 2021–2027 ($ BILLION)
EXHIBIT 37 INCREMENTAL GROWTH BY TECHNOLOGY 2021 & 2027
EXHIBIT 38 US GENE EDITING MARKET BY TECHNOLOGY
EXHIBIT 39 US GENE EDITING MARKET BY TECHNOLOGY: INCREMENTAL GROWTH
EXHIBIT 40 US GENE EDITING MARKET BY TECHNOLOGY: ABSOLUTE GROWTH
EXHIBIT 41 GENOME EDITING TECHNIQUES
EXHIBIT 42 US GENE EDITING MARKET BY CRISPR: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 US GENE EDITING MARKET BY CRISPR 2021–2027 ($ BILLION)
EXHIBIT 44 US GENE EDITING MARKET BY TALEN: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 45 US GENE EDITING MARKET BY TALEN 2021–2027 ($ BILLION)
EXHIBIT 46 US GENE EDITING MARKET BY ZFN: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 47 US GENE EDITING MARKET BY ZFN 2021–2027 ($ BILLION)
EXHIBIT 48 US GENE EDITING MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 49 US GENE EDITING MARKET BY OTHERS 2021–2027 ($ BILLION)
EXHIBIT 50 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 51 US GENE EDITING MARKET BY APPLICATION
EXHIBIT 52 US GENE EDITING MARKET BY APPLICATION: INCREMENT GROWTH
EXHIBIT 53 US GENE EDITING MARKET BY APPLICATION: ABSOLUTE GROWTH
EXHIBIT 54 US GENE EDITING MARKET BY DRUG DISCOVERY & DEVELOPMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 US GENE EDITING MARKET BY DRUG DISCOVERY & DEVELOPMENT 2021–2027 ($ BILLION)
EXHIBIT 56 US GENE EDITING MARKET BY ANIMAL GENE EDITING: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 US GENE EDITING MARKET BY ANIMAL GENE EDITING 2021–2027 ($ BILLION)
EXHIBIT 58 US GENE EDITING MARKET BY PLANT GENE EDITING: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 US GENE EDITING MARKET BY ANIMAL GENE EDITING 2021–2027 ($ BILLION)
EXHIBIT 60 US GENE EDITING MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 US GENE EDITING MARKET BY OTHERS 2021–2027 ($ BILLION)
EXHIBIT 62 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 63 US GENE EDITING MARKET BY END-USER
EXHIBIT 64 US GENE EDITING MARKET BY END-USER: INCREMENT GROWTH
EXHIBIT 65 US GENE EDITING MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 66 US GENE EDITING MARKET BY PHARMA & BIOTECH COMPANIES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 67 US GENE EDITING MARKET BY PHARMA & BIOTECH COMPANIES 2021–2027 ($ BILLION)
EXHIBIT 68 US GENE EDITING MARKET BY ACADEMIC & RESEARCH INSTITUTES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 US GENE EDITING MARKET BY ACADEMIC & RESEARCH INSTITUTES 2021–2027 ($ BILLION)
EXHIBIT 70 US GENE EDITING MARKET BY ANIMAL & PLANT BIOTECH COMPANIES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 US GENE EDITING MARKET BY ANIMAL & PLANT BIOTECH COMPANIES 2021–2027 ($ BILLION)
EXHIBIT 72 US GENE EDITING MARKET BY CROS/CDMOS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 US GENE EDITING MARKET BY CROS/CDMOS 2021–2027 ($ BILLION)
EXHIBIT 74 US GENE EDITING MARKET: KEY VENDORS’ STRENGTHS & CAPABILITIES ASSESSMENT
EXHIBIT 75 US GENE EDITING MARKET: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 76 AGILENT TECHNOLOGIES: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 77 AGILENT TECHNOLOGIES: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 78 AGILENT TECHNOLOGIES: REVENUE BY BUSINESS SEGMENT 2020–2021 ($ MILLION)
EXHIBIT 79 GENSCRIPT: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 80 GENSCRIPT: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 81 GENSCRIPT: REVENUE BY BUSINESS SEGMENT (%)
EXHIBIT 82 MERCK KGAA: TOTAL REVENUE 2019–2021 ($ BILLION)
EXHIBIT 83 MERCK KGAA: REVENUE BY BUSINESS SEGMENT (%)
EXHIBIT 84 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 85 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 86 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2020–2021 ($ MILLION)

LIST OF TABLES


TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 GENE EDITING-BASED INVESTIGATIONAL DRUGS FOR RARE GENETIC DISORDERS (2014–2021)
TABLE 4 GENE EDITING BASED INVESTIGATIONAL DRUGS FOR RARE DISEASES & GENETIC DISORDERS
TABLE 5 GENE EDITING-BASED INVESTIGATIONAL DRUGS FOR HEMOGLOBINOPATHIES
TABLE 6 GENE EDITING-BASED INVESTIGATIONAL DRUGS FOR IMMUNONCOLOGY
TABLE 7 GENE EDITING-BASED INVESTIGATIONAL DRUGS EYE DISORDER TREATMENT
TABLE 8 GENE EDITING-BASED INVESTIGATIONAL DRUGS FOR RARE DISEASES & GENETIC DISORDERS
TABLE 9 CLINICAL TRIALS BY TALEN TECHNOLOGY
TABLE 10 GENE EDITING-BASED CLINICAL TRIALS TO TREAT HUMAN DISEASES
TABLE 11 COMMERCIALLY AVAILABLE DIAGNOSTIC TOOLS BASED ON CRISPR
TABLE 12 PHARMA & BIOTECH COMPANIES’ INVESTMENTS IN GENE EDITING COMPANIES
TABLE 13 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 14 CREATIVE BIOGENE: MAJOR PRODUCT OFFERINGS
TABLE 15 GENSCRIPT: MAJOR PRODUCT OFFERINGS
TABLE 16 MERCK KGAA: MAJOR PRODUCT OFFERINGS
TABLE 17 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 18 TAKARA BIO: MAJOR PRODUCT OFFERINGS
TABLE 19 ARBOR BIOTECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 20 BEAM THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 21 BLUEBIRD BIO: MAJOR PRODUCT OFFERINGS
TABLE 22 CELLECTIS: MAJOR PRODUCT OFFERINGS
TABLE 23 CARIBOU BIOSCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 24 CHARLES RIVER LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 25 CRISPR THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 26 HERA BIOLABS: MAJOR PRODUCT OFFERINGS
TABLE 27 INTEGRATED DNA TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 28 LONZA: MAJOR PRODUCT OFFERINGS
TABLE 29 NEW ENGLAND BIOLABS: MAJOR PRODUCT OFFERINGS
TABLE 30 ORIGENE TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 31 SYNTHEGO: MAJOR PRODUCT OFFERINGS
TABLE 32 TECAN TRADING AG: MAJOR PRODUCT OFFERINGS
TABLE 33 PERKINELMER INC.: MAJOR PRODUCT OFFERINGS
TABLE 34 PRECISION BIOSCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 35 INTELLIA THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 36 INTEGRA THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 37 PAIRWISE: MAJOR PRODUCT OFFERINGS
TABLE 38 SANGAMO THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 39 RECOMBINETICS: MAJOR PRODUCT OFFERINGS
TABLE 40 SYNBIO TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 41 US GENE EDITING MARKET BY PRODUCT 2021–2027 ($ BILLION)
TABLE 42 US GENE EDITING MARKET BY PRODUCT 2021–2027 (%)
TABLE 43 US GENE EDITING MARKET BY TECHNOLOGY 2021–2027 ($ BILLION)
TABLE 44 US GENE EDITING MARKET BY TECHNOLOGY 2021–2027 (%)
TABLE 45 US GENE EDITING MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 46 US GENE EDITING MARKET BY APPLICATION 2021–2027 (%)
TABLE 47 US GENE EDITING MARKET BY END-USER 2021–2027 ($ BILLION)
TABLE 48 US GENE EDITING MARKET BY END-USER 2021–2027 (%)

1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS

4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY

5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 MARKET AT A GLANCE
7 PREMIUM INSIGHTS
7.1 US GENE EDITING MARKET SCENARIO
7.1.1 INSIGHTS BY MARKET DYNAMICS
7.1.2 US GENE EDITING MARKET SEGMENTATIONS
7.1.3 VENDOR ANALYSIS

8 INTRODUCTION
8.1 OVERVIEW
8.1.1 GENE EDITING TECHNIQUES: TOOLS TO CHANGE GENES

9 MARKET OPPORTUNITIES & TRENDS
9.1 EMERGENCE OF NOVEL GENE EDITING TOOLS
9.2 USE OF GENE EDITING IN PERSONALIZED MEDICINE
9.3 INCREASED PHARMA/BIOTECH, VENTURE CAPITAL & GOVERNMENT FUNDING FOR GENE EDITING PROJECTS
9.4 HIGH NUMBER OF GENE EDITING-BASED INVESTIGATIONAL DRUGS

10 MARKET GROWTH ENABLERS
10.1 ADVANCES IN GENOME EDITING PLATFORMS
10.2 LARGE TARGET POPULATION WITH RARE GENETIC DISORDERS
10.3 DEMAND FOR GENE EDITING IN DRUG DISCOVERY & DEVELOPMENT
10.4 DIVERSE APPLICATIONS OF GENE EDITING

11 MARKET RESTRAINTS
11.1 HIGH COST & TIME INVOLVED IN GENE EDITING
11.2 TECHNICAL CHALLENGES RELATED TO GENE EDITING
11.3 ETHICAL & SAFETY CONCERNS ASSOCIATED WITH GENE EDITING

12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.2.1 INSIGHTS BY PRODUCT
12.2.2 INSIGHTS BY TECHNOLOGY
12.2.3 INSIGHTS BY APPLICATION
12.2.4 INSIGHTS BY END-USER
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY

13 PRODUCT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 REAGENTS & CONSUMABLES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 EQUIPMENT & SOFTWARE
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 SERVICES
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST

14 TECHNOLOGY
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 CRISPR
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 TALEN
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 ZFN
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.6 OTHERS
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST

15 APPLICATION
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 DRUG DISCOVERY & DEVELOPMENT
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.4 ANIMAL GENE EDITING
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.5 PLANT GENE EDITING
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.6 OTHERS
15.6.1 MARKET OVERVIEW
15.6.2 MARKET SIZE & FORECAST

16 END-USER
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 PHARMA & BIOTECH COMPANIES
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.4 ACADEMIC & RESEARCH INSTITUTES
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.5 ANIMAL & PLANT BIOTECH COMPANIES
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.6 CROS/CDMOS
16.6.1 MARKET OVERVIEW
16.6.2 MARKET SIZE & FORECAST

17 COMPETITIVE LANDSCAPE
17.1 COMPETITION OVERVIEW
17.1.1 PARTNERSHIPS IN CRISPR AND OTHER NOVEL GENE EDITING TECHNOLOGY
17.2 MARKET SHARE ANALYSIS

18 KEY COMPANY PROFILES
18.1 AGILENT TECHNOLOGIES
18.1.1 BUSINESS OVERVIEW
18.1.2 AGILENT TECHNOLOGIES IN US GENE EDITING MARKET
18.1.3 PRODUCT OFFERINGS
18.1.4 KEY STRATEGIES
18.1.5 KEY STRENGTHS
18.1.6 KEY OPPORTUNITIES
18.2 CREATIVE BIOGENE
18.2.1 BUSINESS OVERVIEW
18.2.2 CREATIVE BIOGENE IN US GENE EDITING MARKET
18.2.3 PRODUCT OFFERINGS
18.2.4 KEY STRATEGIES
18.2.5 KEY STRENGTHS
18.2.6 KEY OPPORTUNITIES
18.3 GENSCRIPT
18.3.1 BUSINESS OVERVIEW
18.3.2 GENSCRIPT IN US GENE EDITING MARKET
18.3.3 PRODUCT OFFERINGS
18.3.4 KEY STRATEGIES
18.3.5 KEY STRENGTHS
18.3.6 KEY OPPORTUNITIES
18.4 MERCK KGAA
18.4.1 BUSINESS OVERVIEW
18.4.2 MERCK KGAA IN US GENE EDITING MARKET
18.4.3 PRODUCT OFFERINGS
18.4.4 KEY STRATEGIES
18.4.5 KEY STRENGTHS
18.4.6 KEY OPPORTUNITIES
18.5 THERMO FISHER SCIENTIFIC
18.5.1 BUSINESS OVERVIEW
18.5.2 THERMO FISHER SCIENTIFIC IN US GENE EDITING MARKET
18.5.3 PRODUCT OFFERINGS
18.5.4 KEY STRATEGIES
18.5.5 KEY STRENGTHS
18.5.6 KEY OPPORTUNITIES
18.6 TAKARA BIO
18.6.1 BUSINESS OVERVIEW
18.6.2 TAKARA BIO IN US GENE EDITING MARKET
18.6.3 PRODUCT OFFERINGS
18.6.4 KEY STRATEGIES
18.6.5 KEY STRENGTHS
18.6.6 KEY OPPORTUNITIES

19 OTHER PROMINENT VENDORS
19.1 ARBOR BIOTECHNOLOGIES
19.1.1 BUSINESS OVERVIEW
19.1.2 PRODUCT OFFERINGS
19.2 BEAM THERAPEUTICS
19.2.1 BUSINESS OVERVIEW
19.2.2 PRODUCT OFFERINGS
19.3 BLUEBIRD BIO
19.3.1 BUSINESS OVERVIEW
19.3.2 PRODUCT OFFERINGS
19.4 CELLECTIS
19.4.1 BUSINESS OVERVIEW
19.4.2 PRODUCT OFFERINGS
19.5 CARIBOU BIOSCIENCES
19.5.1 BUSINESS OVERVIEW
19.5.2 PRODUCT OFFERINGS
19.6 CHARLES RIVER LABORATORIES
19.6.1 BUSINESS OVERVIEW
19.6.2 PRODUCT OFFERINGS
19.7 CRISPR THERAPEUTICS
19.7.1 BUSINESS OVERVIEW
19.7.2 PRODUCT OFFERINGS
19.8 HERA BIOLABS
19.8.1 BUSINESS OVERVIEW
19.8.2 PRODUCT OFFERINGS
19.9 INTEGRATED DNA TECHNOLOGIES
19.9.1 BUSINESS OVERVIEW
19.9.2 PRODUCT OFFERINGS
19.10 LONZA
19.10.1 BUSINESS OVERVIEW
19.10.2 PRODUCT OFFERINGS
19.11 NEW ENGLAND BIOLABS
19.11.1 BUSINESS OVERVIEW
19.11.2 PRODUCT OFFERINGS
19.12 ORIGENE TECHNOLOGIES
19.12.1 BUSINESS OVERVIEW
19.12.2 PRODUCT OFFERINGS
19.13 SYNTHEGO
19.13.1 BUSINESS OVERVIEW
19.13.2 PRODUCT OFFERINGS
19.14 TECAN TRADING AG
19.14.1 BUSINESS OVERVIEW
19.14.2 PRODUCT OFFERINGS
19.15 PERKINELMER INC
19.15.1 BUSINESS OVERVIEW
19.15.2 PRODUCT OFFERINGS
19.16 PRECISION BIOSCIENCES
19.16.1 BUSINESS OVERVIEW
19.16.2 PRODUCT OFFERINGS
19.17 INTELLIA THERAPEUTICS
19.17.1 BUSINESS OVERVIEW
19.17.2 PRODUCT OFFERINGS
19.18 INTEGRA THERAPEUTICS
19.18.1 BUSINESS OVERVIEW
19.18.2 PRODUCT OFFERINGS
19.19 PAIRWISE
19.19.1 BUSINESS OVERVIEW
19.19.2 PRODUCT OFFERINGS
19.20 SANGAMO THERAPEUTICS
19.20.1 BUSINESS OVERVIEW
19.20.2 PRODUCT OFFERINGS
19.21 RECOMBINETICS
19.21.1 BUSINESS OVERVIEW
19.21.2 PRODUCT OFFERINGS
19.22 SYNBIO TECHNOLOGIES
19.22.1 BUSINESS OVERVIEW
19.22.2 PRODUCT OFFERINGS

20 REPORT SUMMARY
20.1 KEY TAKEAWAYS
20.2 STRATEGIC RECOMMENDATIONS

21 QUANTITATIVE SUMMARY
21.1 MARKET BY PRODUCT
21.2 MARKET BY TECHNOLOGY
21.3 MARKET BY APPLICATION
21.4 MARKET BY END-USER

22 APPENDIX
22.1 ABBREVIATIONS

Select a license type that suits your business needs

Single User Licence

$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email

5 User Licence

$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Corporate Licence

$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Datasheet Licence

$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Frequently Asked Questions

What is the expected growth of the U.S. gene editing market?

The U.S. gene editing market size was valued at USD 2.90 billion in 2021 and is expected to reach USD 9.16 billion by 2027.

What is the growth rate of the U.S. gene editing market?

The U.S. gene editing market is growing with a CAGR of 21.13% from 2022 to 2027.

Who are the key players in the U.S. gene editing market?

Key players in the U.S. gene editing market are Agilent Technologies, Creative Biogene, Genscript, Merck KGaA, Thermo Fisher Scientific, and Takara Bio.

What are the latest trends in the U.S. gene editing market?

The emergence of novel gene editing tools, the rise in demand for gene editing in personalized medicine, and increasing pharma/biotech, venture capital, & government funding for gene editing projects are some of the latest trends in the U.S. gene editing market.

What factors will drive the U.S. gene editing market?

The factors driving the U.S. gene editing market are advances in genome editing platforms, increasing target population with rare, genetic & highly complex diseases, and high demand for gene editing in drug discovery & development.

How much is the CRISPR industry worth?

The CRISPR segment dominates the U.S. gene editing market at 63.49%. The CRISPR segment was valued at USD 1.84 billion in 2021.